key: cord-0702419-1vmicejr
authors: Prattes, Juergen; Wauters, Joost; Giacobbe, Daniele Roberto; Salmanton-García, Jon; Maertens, Johan; Bourgeois, Marc; Reynders, Marijke; Rutsaert, Lynn; Van Regenmortel, Niels; Lormans, Piet; Feys, Simon; Reisinger, Alexander Christian; Cornely, Oliver A.; Lahmer, Tobias; Valerio, Maricela; Delhaes, Laurence; Jabeen, Kauser; Steinmann, Joerg; Chamula, Mathilde; Bassetti, Matteo; Hatzl, Stefan; Rautemaa-Richardson, Riina; Koehler, Philipp; Lagrou, Katrien; Hoenigl, Martin
title: Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients– a multinational observational study by the European Confederation of Medical Mycology
date: 2021-08-26
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.08.014
sha: 49effa3f8770505e6195a5bd14deb56f0343e8ef
doc_id: 702419
cord_uid: 1vmicejr

OBJECTIVES: Coronavirus disease 2019 (COVID-19) associated pulmonary aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The objectives of this multinational study were to determine the prevalence of CAPA in patients with COVID-19 in intensive care units (ICU) and to investigate risk factors for CAPA as well as outcome. METHODS: The European Confederation of Medical Mycology (ECMM) conducted a multinational study including 20 centers from nine different countries to assess epidemiology, risk factors, and outcome of CAPA. CAPA was defined according to the 2020 ECMM/ISHAM consensus definitions. RESULTS: A total of 592 patients were included in this study, including 11 (1.9%) patients with histologically proven CAPA, 80 (13.5%) patients with probable CAPA, 18 (3%) with possible CAPA and 483 (81.6%) without CAPA. CAPA was diagnosed a median of 8 days (range 0-31) after ICU admission predominantly in older patients [adjusted hazard ratio (aHR) 1.04 per year; 95%CI 1.02-1.06] with any form of invasive respiratory support (HR 3.4; 95%CI 1.84-6.25) and receiving tocilizumab (HR 2.45; 95%CI 1.41-4.25). Median prevalence of CAPA per center was 10.7% (range 1.7%-26.8%). CAPA was associated with significantly lower 90-day ICU survival rate (29% in patients with CAPA versus 57% in patients without CAPA; Mantel-Byar p<0.001) and remained an independent negative prognostic variable after adjusting for other predictors of survival (HR=2.14; 95%CI: 1.59-2.87, p<=0.001). CONCLUSION: Prevalence of CAPA varied between centers. CAPA was significantly more prevalent among older patients, patients receiving invasive ventilation and patients receiving tocilizumab, and was an independent strong predictor of ICU mortality.

The release of danger-associated molecular patterns (DAMPs) during coronavirus disease-19 acute respiratory failure (ARF) may contribute to a highly permissive inflammatory environment that favors pathogenesis of COVID-19 associated pulmonary aspergillosis (CAPA) [1, 2] . CAPA has first been described in early 2020 in case reports or small case series [3] [4] [5] . Since then, larger case series and cohorts have followed [1, [6] [7] [8] [9] [10] and CAPA is now considered a potential life-threatening secondary infection in a significant number of critically ill COVID-19 patients [11] . Reported CAPA prevalence rates vary widely between different studies (3% -33%) [12] [13] [14] [15] [16] . Several factors may explain the wide variation of CAPA rates including differences in awareness and local diagnostic strategies (e.g., bronchoscopies not done [17] ), as well as various different criteria applied for definition of aspergillosis in COVID-19 patients [16, 18] .

The recently published consensus criteria for definition of CAPA [19] will lead to more uniform CAPA classification across studies and will thereby increase comparability of results. According to those consensus criteria, diagnosis of CAPA relies on microbiological work-up, clinical characteristics, and imaging studies, however, diagnosis of CAPA remains a complex clinical challenge [20] .

Several risk factors for CAPA have been described in single center cohorts, including azithromycin use, use of corticosteroids, use of anti-interleukin-6 treatment and underlying pulmonary disease [6, 7, 21, 22] , however, for identification of factors that would allow for targeted prevention efforts larger prospective cohort studies are needed. While some single center studies have reported that CAPA was associated with higher mortality rates [6, 7] , larger studies are needed to elucidate the role of CAPA in overall mortality in COVID-19 ARF.

To determine the prevalence of CAPA in patients with COVID-19 in ICUs and to investigate risk factors for CAPA as well as potential associations with mortality, the ECMM has initiated a multicenter, multinational cohort study comparing risk factors, and clinical outcomes in patients with COVID-19 associated ARF with and without CAPA.

J o u r n a l P r e -p r o o f

We performed a multicenter, multinational cohort study including 20 centers in nine countries: Austria (n=2), Belgium (n=4), France (n=3), Germany (n=4), Italy (n=2), Pakistan (n=1), Spain (n=1), United Kingdom (n=1) and United States (n=2). The main objectives of this study were to assess the epidemiology of CAPA, risk factors associated with development of CAPA and outcomes of patients with CAPA on intensive care unit (ICU). The study was initiated in March 2020 and data entry was open until May 2021.

All participating centers were invited to provide data on demographics, underlying medical conditions, risk factors for invasive fungal infections, details on diagnostic work-up (including radiological and microbiological data), treatment and outcome via an online case report form. Based on the dynamic evolution of the COVID-19 pandemic in 2020 the study protocol did not include target enrollment For data acquisition and storage, we used FungiScope® (NCT 01731353), providing an anonymized electronic case report form accessible through www.clinicalsurveys.net [23] . Results on treatment and J o u r n a l P r e -p r o o f diagnosis [24] as well as a few of the included CAPA cases have been published in the meantime [5, [24] [25] [26] .

For classification of cases, we used the 2020 ECMM/ISHAM consensus criteria [19] . According to the criteria, patients were categorized as either proven pulmonary and/or tracheobronchial CAPA, probable pulmonary and/or tracheobronchial CAPA, possible pulmonary and/or tracheobronchial CAPA or no evidence for CAPA.

All statistical analyses were performed using IBM SPSS Statistics 25 (SPSS Inc., Chicago, IL, USA) and

Stata (Windows version 16.0, Stata Corp., Houston, TX, USA). Baseline characteristics between patients with and without disease progression or death during follow-up were compared with rank-sum tests, 

We performed a large multinational study on CAPA in critically ill COVID-19 patients and found that prevalence varied widely between centers with a median prevalence of 11%. CAPA was diagnosed at a median of 8 days after ICU admission and was more often diagnosed in elderly patients who needed invasive ventilation and received tocilizumab. CAPA was associated with devastating mortality, and remained an independent negative prognostic variable after adjusting for other predictors of survival

The true prevalence of CAPA is still a matter of debate and depends on various factors including socioeconomic factors (e.g. general health condition of a population; access to healthcare institutions, etc.), local epidemiology and/or seasonal variations in the spread of Aspergillus spores [27] , local awareness regarding fungal infections in critically ill patients and the availability and turnaround time of diagnostic tools to diagnose CAPA (e.g. bronchoscopies [17] , easy access to CT-scans, fungal biomarkers, etc.), and also criteria used for classification of CAPA. The importance of bronchoscopy was highlighted in this cohort where galactomannan testing from BALF had higher sensitivity (77% with 1.0 ODI cutoff) than from serum (19%) [24] . In this study we have classified all patients according to the recently published standardized ECMM/ISHAM consensus definitions for CAPA [19] , and found a median CAPA prevalence among the participating centers of 10.7%, ranging between 1.7% and 26.8%. This range is similar to the reported CAPA rates in the literature so far, even if a wide range of definitions had previously been used [8] .

Understanding the main drivers and risk factors for development of CAPA is important, to be able to better target aggressive screening or even use of antifungal prophylaxis to prevent CAPA in high risk COVID-19 patients. In our multivariable model need for invasive ventilation, older age and treatment with tocilizumab were significantly associated with increased probability of CAPA development. These variables may primarily reflect patients with more severe COVID-19, more severe lung damage and impaired immune response in the elderly. However, other factors described before to be associated with CAPA development like the use of systemic corticosteroids [7] , or the use of azithromycin [21] , were not J o u r n a l P r e -p r o o f significantly associated with CAPA in our study. Whereas, corticosteroids are a well-known risk factor for impaired neutrophil function and thus development of invasive fungal infections, it is now considered standard of care treatment in critically ill COVID-19 patients and therefore less likely to turn out as significant predictor of CAPA [28] . Indeed, the majority of patients with severe COVID-19 in this study received systemic corticosteroids, which is in contrast to some of the earlier studies where use of systemic corticosteroids was less frequent [6, 7, 29] . Tocilizumab turned out as risk factor for CAPA development in our cohort. The use of anti-IL-6 treatment or inhibition of Janus kinase seems to increase the overall risk of secondary infections in critically ill COVID-19 patients, but there was no convincing evidence from larger studies currently that risk for CAPA is increased by the use of anti-IL-6 treatment [6, 29] , which is in contrast to our finding. Nevertheless, as treatment strategies for critical COVID-19 have changed several times within the last year, comparison among the different trials and different study centers is difficult, as is a potential impact of combinations of different immunosuppressive/immunomodulatory treatment regimens.

Some previous, single center studies, have indicated that CAPA may prolong stay in hospital and invasiveness of ventilation [29] , and may also be associated with higher mortality compared to non-CAPA patients [6, 7] , while others did not show any impact on mortality [12] . Our results show that CAPA was associated with a nearly 2-fold increased risk of ICU mortality compared to patients who did not develop CAPA (71% versus 43%), even after accounting for various other factors that impact mortality. This finding supports the hypothesis that CAPA development has negatives effects on overall outcome in critically ill COVID-19 patients. Whether or not, this is a causal association and therefore prevention of CAPA by applying antifungal prophylaxis strategies may improve the overall outcome of these patients, needs to be clarified in future, randomized-controlled trials (RCT). For influenza associated invasive aspergillosis results of a RCT were recently published that showed no significant benefit of prophylaxis due to the fact that invasive aspergillosis often occurred within few hours of ICU admission [30] . Given that CAPA seems to develop later, prophylaxis may be more promising. In conclusion, CAPA was more often diagnosed in elderly patients, in patients who needed invasive ventilation and in patients who received tocilizumab and was strongly associated with mortality, remaining an independent negative prognostic variable after adjusting for other predictors of survival.

Future studies should evaluate whether antifungal prophylaxis may reduce CAPA prevalence.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Jean-Jacques Tudesq (Medical Intensive Care Unit, Saint-Louis Teaching Hospital

Paolo Pelosi (Department of Surgical Sciences and Integrated Diagnostics

COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment

Aspergillus fumigatus and aspergillosis: From basics to clinics

Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -A case report

COVID-19-associated Pulmonary Aspergillosis

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

COVID-19-Associated Pulmonary Aspergillosis

Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience

G. Mycoses Study, M. European Confederation of Medical, Invasive Aspergillosis as an Underrecognized Superinfection in COVID-19, Open Forum Infectious Diseases

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia

Invasive Fungal Disease complicating COVID-19: when it rains it pours

Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis-A simulation study

Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches

Infectious Diseases Fungal Infection Study, E.S.G.f.I.i.C.I. Patients, M. Interregional Association of Clinical, C. Antimicrobial, N. Medical Mycology Society of, A. Medical Mycology Society of China Medicine Education, H. Infectious Diseases Working Party of the German Society for

Detection of Unsuspected Coronavirus Disease 2019 Cases by Computed Tomography and Retrospective Implementation of the Radiological Society of North America/Society of Thoracic Radiology/American College of Radiology Consensus Guidelines

Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort

COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series

FungiScope(™) -Global Emerging Fungal Infection Registry

Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry

COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan

Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia

The human lung and Aspergillus: You are what you breathe in?

Dexamethasone in Hospitalized Patients with Covid-19

COVID-19 Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised

N (%) 173 (29.2)

Underlying Diseases Cardiovascular disease, N (%)

Maximal Ventilation on ICU Non-invasive Ventilation, N (%)

Invasive Mechanical Ventilation

Days (median

Abbreviations: CAPA = COVID-19 associated pulmonary aspergillosis

ECMO = extracorporeal membrane oxygenation

109 or 483 patients, respectively, unless stated otherwise. In case % were calculated for less than the maximal number of patients, data for some patients were missing and the actual denominator is displayed $ active malignancy is defined as solid malignancies for which treatment had been administered within six months

Author contributions: